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IMPORTANCE Immune checkpoint inhibitors have demonstrated atypical response patterns,
whichmay not be fully captured by conventional response criteria. There is a need to better
understand the potential benefit of continued immune checkpoint inhibition beyond
progression.
OBJECTIVE To evaluate the safety and potential benefit of nivolumab (anti–programmed cell
death receptor 1) monotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)
v1.1-defined progression.
DESIGN, SETTING, AND PARTICIPANTS Pooled, retrospective analysis of data from phase 3
trials of nivolumab in treatment-naive patients with advancedmelanoma (CheckMate 066 or
CheckMate 067) conducted at academic and clinical cancer centers. Participants were
patients treated beyond first disease progression, defined as those who received their last
dose of nivolumabmore than 6weeks after progression (TBP group); and patients not
treated beyond progression, who discontinued nivolumab therapy before or at progression
(non-TBP group). Data analyses were conducted fromNovember 6, 2015, to January 11, 2017.
INTERVENTIONS Nivolumab (3mg/kg every 2 weeks) administered until progression or
unacceptable toxic effects. Patients could be treated beyond progression if deriving apparent
clinical benefit and tolerating study drug, at the investigator’s discretion.
MAIN OUTCOMES ANDMEASURES Tumor response and safety in TBP and non-TBP patients.
RESULTS Among 526 randomized patients (39% [n = 203] female; median age, 62 years
[range, 18-90 years]), 306 (58%) experienced disease progression, including 85 (28%) TBP
patients and 221 (72%) non-TBP patients. Twenty-four (28%) of the TBP patients had a target
lesion reduction of greater than 30% after progression compared with baseline (TBP>30%
group). At the time of this analysis, 65 (76%) TBP patients and 21 (87%) TBP>30% patients
were still alive; 27 (32%) and 11 (46%), respectively, continued to receive treatment. Median
(range) time from progression to last dose of treatment was 4.7 (1.4-25.8) months for TBP
patients and 7.6 (2.4-19.4) months for TBP>30% patients. Median (range) time from
progression to greater than 30% tumor reduction was 1.4 (0.2-7.0) months.
Treatment-related select grade 3 to 4 adverse events were similar in the TBP and non-TBP
groups (5 [6%] and 9 [4%], respectively).
CONCLUSIONS AND RELEVANCE A substantial proportion of selected patients treatedwith
frontline nivolumab whowere clinically stable and judged to be eligible for treatment beyond
RECIST v1.1–defined progression by the treating investigators derived apparent clinical
benefit without compromising safety. Further analysis will help define the potential benefit of
continued nivolumab treatment beyond progression.
TRIAL REGISTRATION clinicaltrials.gov Identifiers: NCT01721772 (CheckMate 066) and
NCT01844505 (CheckMate 067)
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Immune checkpoint inhibitors, which enhance antitumorimmune response,1-3 are associated with atypical re-sponse patterns4,5 that may not be fully captured by con-
ventional responsecriteriasuchasResponseEvaluationCriteria
in Solid Tumors (RECIST).6 These atypical response patterns
includeresponses followinganapparent increase in tumorbur-
den (“pseudoprogression”) and responses in the presence of
new lesions. In advanced melanoma, immune-related re-
sponses have been observed in approximately 10% of pa-
tients treatedwith ipilimumab (anti–cytotoxic T-lymphocyte
antigen4),5 and in approximately 7%to9%ofpatients treated
with nivolumab or pembrolizumab (anti–programmed cell
death receptor 1 [anti–PD-1]).7-9
Nivolumab isa fullyhumanmonoclonal IgG4antibodythat
selectively blocks the interaction between PD-1 on activated
Tcells and its ligands, programmedcell death ligands 1 (PD-L1)
and2(PD-L2),ontumorcellsaswellastumor-infiltratingimmune
cells.10-13 Basedonphase3 trial data showing improvedoverall
survival (OS)andprogression-freesurvival (PFS)comparedwith
dacarbazine (CheckMate066)7and improvedPFSandobjective
response rate vs ipilimumab (CheckMate 067),14 nivolumab
monotherapywasapprovedforthetreatmentofadvancedmela-
noma inmany countries around theworld.
InCheckMate066,treatment-naivepatientswithBRAFwild-
type melanoma treated with nivolumab had an improved OS
comparedwith thosewho received dacarbazine (prepared as a
citrate salt) (hazard ratio for death, 0.42; 99.8% CI, 0.25-0.73;
P < .001).Whereas the objective response ratewith nivolumab
was high (40%), approximately 30% of patients experienced a
best overall response of progressive disease.7 Similarly, in
CheckMate067, themedianPFSwassignificantly longer forpa-
tientswhoreceivednivolumabplusipilimumab(11.5months;95%
CI,8.9-16.7months)ornivolumabmonotherapy(6.9months;95%
CI,4.3-9.5months)comparedwithipilimumabmonotherapy(2.9
months;95%CI,2.8-3.4months;P < .001forbothcomparisons).14
Progressivediseasewasreportedin23%,38%,and49%ofpatients
treated with the combination, nivolumab monotherapy, and
ipilimumabmonotherapy, respectively.
Althoughdiseaseprogression is considered failureof treat-
ment fornonimmunotherapeuticagents, resulting in treatment
discontinuation, thepossibilityofdelayed, immune-related re-
sponses suggests that patients with disease progression could
benefit fromcontinued treatmentwith immunecheckpoint in-
hibitors.Therefore,acrossthenivolumabdevelopmentprogram,
patients were permitted to continue study treatment after ini-
tial investigator-assessedRECISTv1.1–definedprogression,pro-
vided that theywere considered to be deriving clinical benefit
andtoleratingthestudydrug.Theobjectiveof this retrospective
analysis was to evaluate the safety and potential benefit of
nivolumabmonotherapybeyond the firstRECISTv1.1–defined
progression in patientswith advancedmelanoma.
Methods
Study Design and Treatment
Thisanalysispooleddata frompatients treatedwithnivolumab
monotherapy in CheckMate 066 (n = 206)7 or CheckMate 067
(n = 313) (Figure 1).14 Patients receivednivolumab, 3mg/kg, ev-
ery2weeksby intravenous infusionuntildiseaseprogressionby
RECISTv1.1criteria6orunacceptable toxiceffects.Theprotocols
forCheckMate066andCheckMate067state thatpatientscould
betreatedbeyondfirstprogressionprovidedthat theyexhibited
investigator-assessedclinicalbenefitwithoutsubstantialadverse
effects relatedtonivolumab.Assessmentofclinicalbenefit took
intoaccountwhetherthepatientwasclinicallydeterioratingand
unlikelytoreceivefurtherbenefit fromcontinuedtreatment. In-
vestigatorsselectedpatients forTBPafterconsultationwithand
approval from the studymonitors.
Inthisanalysis,patientstreatedbeyondfirstdiseaseprogres-
sion were defined as those who received their last dose of
nivolumabmore than6weeksafterprogression (TBPgroup).A
subgroup of these patients that had greater than 30% tumor
reductionintarget lesionafterprogressionwhencomparedwith
baselinewasevaluatedseparately(TBP>30%group).Patientsnot
treated beyondprogressiondiscontinuednivolumabbefore or
at RECIST-defined progression (non-TBP group).
Patients
Eligiblepatientshadhistologicallyconfirmedunresectablestage
IIIor IVmalignantmelanomaandhadreceivednopriorsystemic
therapy for advanceddisease.7,14 Patientswereat least 18years
ofage,withmeasurabledisease,andanEasternCooperativeOn-
cologyGroup(ECOG)performancestatusof0or 1.Patientswith
activebrainmetastases,ocularmelanoma,orautoimmunedis-
easewereexcludedfrombothstudies. InCheckMate066,allpa-
tientshadBRAFwild-typemelanoma;inCheckMate067,patients
with BRAF wild-type or BRAF-mutated melanoma were
eligible.7,14Allpatientsprovidedwritten informedconsent.The
protocolswereapprovedbyeither the relevant institutional re-
viewboardsorethicscommitteesateachinvestigator’sstudysite.
Thestudieswereconducted inaccordancewith theDeclaration
ofHelsinkiwithgoodclinicalpracticeasdefinedbythe Interna-
tional Conference onHarmonisation.
Progression-Free Survival, Overall Survival,
Tumor Response, and Safety Assessments
Progression-free survival was defined as time from random-
ization to investigator-assessed first clinical or radiographic
Key Points
Question Can patients with treatment-naive advancedmelanoma
derive apparent clinical benefit from nivolumab treatment beyond
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined
progression without compromising safety?
Findings In this pooled, retrospective analysis of 85
treatment-naive patients with advancedmelanomawho
continued nivolumab treatment beyond RECIST v1.1-defined
progression in phase 3 clinical trials (CheckMate 066, CheckMate
067), 28% had a target lesion reduction of greater than 30% after
progression compared with baseline, with no new or unexpected
adverse events.
Meaning Continued treatment with nivolumabmay be an option
to achieve further benefit without compromising safety in some
patients with advancedmelanoma.
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RECIST progression, or death. Overall survival was defined
as time from randomization to death. Tumor assessments
included objective response rate based on investigator-
assessed RECIST v1.1 criteria, time to response, and dura-
tion of response, defined as time from complete or partial
response to first disease progression. Tumors were assessed
at baseline, every 6 weeks from randomization for the first
year, and every 12 weeks thereafter, until disease progres-
sion or treatment discontinuation, whichever occurred
later. After treatment discontinuation, patients were evalu-
ated every 3 months for survival and safety. Adverse events
(AEs) were graded using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events v4.0. Select
AEs, defined as those with a potential immunologic cause,
were analyzed by organ category.
Statistical Analyses
Objective response ratewas defined as the number of patients
with a best overall responseof complete or partial responsedi-
videdbythenumberofrandomizedpatientsforeachgroup,with
Figure 1. Consolidated Standards of Reporting Trials FlowDiagram for Patient Disposition,
Showing Patient Subgroups for Analysis
1814 Assessed for eligibility
518
1296
Screened in CheckMate 066
Enrolled in CheckMate 067
100 Excluded from CheckMate 066
100 Reason not specified
351 Excluded from CheckMate 067
7
45
5
1
7
273
13
Adverse events
Withdrew consent
Death
Lost to follow-up
Poor/noncompliance
No longer met study criteria
Other
1363 Randomized
418 in CheckMate 066: 210 to nivolumab, 
208 to dacarbazine; 945 in CheckMate 067: 
316 to nivolumab, 314 to nivolumab +
ipilimumab, 315 to ipilimumab
837 Excluded from the pooled analysis
(allocated to treatment other than
nivolumab monotherapy)
220 Excluded from analysis
220 No progression
Not treated beyond progression 
(non-TBP group)
221 85 Treated beyond progression (TBP group)
24 With >30% reduction in tumor 
burden (TBP>30% group)
24 TBP>30% group analyzed for efficacy 
and safety
85 TBP group analyzed for efficacy
and safety
Non-TBP group analyzed for
efficacy and safety
221
Included in the pooled analysis
526 Allocated to nivolumab monotherapy
519 Received allocated intervention
206
313
7 Did not receive allocated 
intervention
in CheckMate 066
in CheckMate 067
306 Analyzed with RECIST-defined 
progression
Patients were assessed for eligibility
and randomized in 2 separate phase 3
trials, CheckMate 066 and
CheckMate 067.7,14 Other treatments
(in addition to nivolumab
monotherapy) to which patients were
randomized comprised dacarbazine
(n = 208) in CheckMate 066 and
nivolumab plus ipilimumab (n = 314)
or ipilimumabmonotherapy (n = 315)
in CheckMate 067. TBP indicates
treatment beyond progression.
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2-sided, 95% CIs for the response rate based on the Clopper-
Pearson method. Progression-free survival and OS were esti-
mated using Kaplan-Meier methodology; 2-sided, 95% CIs for
median PFS and OS were computed by the Brookmeyer and
Crowleymethod.Tumorburdenchange(sumofdiametersoftar-
get lesions)over timeforeachpatientwasdisplayedgraphically.
Results
Patient Characteristics at Baseline and Progression
Median time from randomization to last known date alive or
death in the TBP, non-TBP, and TBP>30% groups was 14.3
(range, 5.0-27.9), 9.9 (range, 0.3-27.6), and 15.0 (range, 10.4-
24.7) months, respectively. Of 526 patients allocated to
nivolumabmonotherapy, 306 (58%) experienceddiseasepro-
gression; 85 (28%) patients with progressing disease were in
theTBPgroupand221 (72%)were in thenon-TBPgroup(eTable
1 in the Supplement; Figure 1). The remaining 220 (42%) pa-
tients didnot experiencedisease progressionwithnivolumab
(Figure1).Amongthe85TBPpatients,30were fromCheckMate
066 and 55 were from CheckMate 067. Twenty-four TBP pa-
tients (28%) had a target lesion reduction of greater than 30%
afterprogressionwhencomparedwithbaseline (eTable 1 in the
Supplement; Figure 1).
Formal hypothesis testing was not conducted; however,
numerical differenceswere noted between TBP and non-TBP
patients.Relative tonon-TBPpatients,TBPpatientsweremore
likely tohaveabaselineECOGperformancestatusof0(71 [84%]
vs 145 [66%]) and less likely to have poor prognostic features
atbaseline, including stageM1cdisease (41 [48%]vs 152 [69%])
and lactate dehydrogenase (LDH) levels above theupper limit
ofnormal (ULN) (25 [29%]vs109[49%]) (eTable 1 in theSupple-
ment).Relative to theTBPgroupoverall, TBPpatientswhohad
a tumor reduction of greater than 30% after first progression
were less likely to have poor prognostic features at baseline
(M1c disease: 8 [33%] vs 41 [48%]; LDH > ULN: 5 [21%] vs 25
[29%]; LDH > 2 × ULN: 0 vs 4 [5%]). Twenty percent of pa-
tients in both the TBP (17 patients) and non-TBP (45 patients)
groups, and 33% of those in the TBP>30% group (8 patients),
hadBRAFmutation–positivemelanoma. PatientswithPD-L1–
positive status (5%cutoff) included 23 (27%)TBPpatients, 43
(19%) non-TBP patients, and 5 (21%) TBP>30% patients.
TheTBPpatientsweremorelikelythanthenon-TBPpatients
to have first progressiondefinedby either an increase in target
lesionsorappearanceofnewlesions,but less likely tohaveboth
of thesediseasecharacteristics together (Table1).Fewerpatients
in the TBP than non-TBP group had LDH levels above the ULN
atprogression (19 [22%]vs132 [60%]),butmorepatientshadan
ECOGperformance statusof0 (66 [78%]vs 111 [50%]) (Table 1).
Noneof theTBP>30%patientshadLDHlevelsabove theULNat
progressionand20(83%)hadanECOGperformancestatusof0.
Themedianchangeintumorvolume(size intarget lesionsasper
RECISTv1.1criteria)atprogressionwasanincreaseof15%(range,
−100%to353%)innon-TBPpatientsandadecreaseof9%(range,
−100% to 176%) and 45% (range, −87% to 64%) in TBP and
TBP>30%patients, respectively. InTBPpatients,progression in
manycaseswasdue to theappearanceofnew lesionsdespite a
decrease in target lesions (Table 1).
Response Before First Progression and Time to Progression
In theperiod fromthe start ofnivolumab treatment to first dis-
ease progression, non-TBP and TBP groups had a similar ob-
jective response rate (33 [15%] vs 16 [19%]), median PFS (2.6
[95%CI, 2.30-2.66]vs2.8 [95%CI, 2.69-3.15]months), andme-
dian time to objective response (non-TBP, 2.6 [range, 1.9-5.3]
months;TBP,2.6 [range,2.0-7.6]months).Comparedwithnon-
TBP patients, TBP patients had a shorter median duration of
objective response (4.4 vs 5.6 months). The majority of TBP
patientswhoexperiencedRECISTv1.1-definedprogressiondid
so at the time of first scan (Figures 2 and 3).
Duration of Treatment and Survival
IntheTBPgroup,65patients (76%)werealiveand27(32%)were
continuingtreatmentat thetimeof theanalysis (Figure2). Inthe
TBP>30%group,21patients (87%)werealiveand11 (46%)were
Table 1. Patient Characteristics at Progression
Characteristic
Patients Who Experienced Disease Progression (n = 306)
Non-TBP
(n = 221)
TBP
(n = 85)
TBP>30%a
(n = 24)
Eastern Cooperative Oncology Group performance status of 0, No. (%) 111 (50) 66 (78) 20 (83)
LDH > ULN, No. (%) 132 (60) 19 (22) 0
LDH > 2 × ULN, No. (%) 61 (28) 2 (2) 0
Change in tumor volume at progression, mean (range), %b 15 (−100 to 353) −9 (−100 to 176) −45 (−87 to 64)
Progression due to increase in target lesions only, No. (%)c 35 (16) 24 (28) …
Progression due to appearance of new lesions only, No. (%)c 67 (30) 39 (46) …
Increase in target lesions and appearance of new lesions, No. (%) 65 (29) 16 (19) …
Progression in nontarget lesions only, No. (%) 54 (24) 6 (7) …
Abbreviations: LDH, lactate dehydrogenase; TBP, treatment beyond
progression; ULN, upper limit of normal.
a The TBP>30% group is a subset of the TBP group. Patients in this subset had
greater than a 30% tumor reduction in target lesion after progression
compared with baseline.
b Change in size of target lesions per Response Evaluation Criteria in Solid
Tumors v1.1; does not include new lesions.
c The percentage of patients with an increase in target lesions and/or
appearance of new lesions does not total 100% because not all factors
attributed to progressive disease are shown in the table (eg, progression of
nontarget lesions).
Research Original Investigation Nivolumab for Patients With AdvancedMelanoma Treated Beyond Progression
E4 JAMAOncology Published online June 29, 2017 (Reprinted) jamaoncology.com
© 2017 American Medical Association. All rights reserved.
Downloaded From: http://jamanetwork.com/ by a Knowledgepoint360 User  on 06/29/2017
continuing treatment (Figure 2). The median number of
nivolumab doses received after progression was 9.0 (range,
3-53) for the TBP group overall and 16.5 (range, 5-41) for the
TBP>30%group.Themediantimefromprogressionto lastdose
of study treatmentwas4.7months (range, 1.4-25.8months) for
TBP patients and 7.6 months (range, 2.4-19.4 months) for
TBP>30%patients.Themediantimefromprogressiontogreater
than 30% tumor reduction compared with baseline was 1.4
months (range,0.2-7.0months) inTBP>30%patients.Of the85
TBPpatients,36(42%)hadareductionintumorburdenafterfirst
progression(eFigure1 intheSupplement).TheTBPpatientswho
achieved subsequent tumor reduction after initial diseasepro-
gression did so beforeweek 24 (Figure 3).
MedianOSfromrandomizationtonivolumabtreatmentwas
not reached (95%CI, 21.5 to not reached) for TBP patients and
was10.6months(95%CI,8.1-14.2months) fornon-TBPpatients,
with24-monthOSratesof59%(95%CI,36%-76%)and25%(95%
CI, 16%-35%), respectively (eFigure 2 in the Supplement).
Overall Safety
Any-grade, treatment-related selectAEswere similar, but gen-
erally occurredmore frequently, in the TBP group than in the
Figure 3. Tumor Burden Change Over Time in 24 Patients Treated Beyond ProgressionWith Greater Than 30%
Tumor Reduction in Target Lesion After Progression ComparedWith Baseline
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non-TBP group (Table 2). The frequency of treatment-related
select grade 3 to4AEswas similar in non-TBP andTBPgroups
(9 [4%]and5[6%], respectively).Themostcommontreatment-
related select AEs of any grade involved the skin (58 [26%] in
thenon-TBPgroupand43 [51%] in theTBPgroup) andof grade
3 to 4 involved the liver (4 [2%] in the non-TBP and 2 [2%] in
the TBP group). In an exposure-adjusted safety analysis, the
incidence of treatment-related AEs was lower in TBP vs non-
TBP patients (eTable 2 in the Supplement).
Subsequent Therapy
Following first progression, fewerpatients in theTBPgroup re-
ceived subsequent anticancer treatment than in the non-TBP
group (56 [66%]vs 166 [75%]) (eTable3 in theSupplement).Al-
though the typeof subsequent anticancer treatments received
was similar in both groups (eTable 3 in the Supplement),more
patientsintheTBPgroupthaninthenon-TBPgroupreceivedsur-
gery (19 [22%]vs 28 [13%]) and fewer received any subsequent
systemic therapy (41 [48%]vs 146 [66%]).AmongTBP>30%pa-
tients, 1 (4%) received surgery and9 (37%) received any subse-
quent systemic therapy (eTable3 in theSupplement).Thebrain
was themost common site of subsequent radiotherapy in TBP
andnon-TBPgroups(2[2%]and9[4%]ofpatients, respectively)
(eTable4 in theSupplement).Themost commontypeof subse-
quentsurgerywas local tumor treatmentsurgery,whichwasre-
ported in 7 (8%) of TBPpatients and 3 (1%) of non-TBPpatients
(eTable 4 in the Supplement).
Discussion
This retrospective, pooled analysis of data from the phase 3
studiesCheckMate066andCheckMate067suggests thatapro-
portion of patients with treatment-naive advanced mela-
nomawhoreceivenivolumabbeyondRECISTv1.1-definedpro-
gressionmayderiveapparentclinicalbenefit.Althoughthedata
in this report are still immature, given the lackofOSdata from
CheckMate 067, 76% of patients treated with nivolumab be-
yond first progression were alive at the time of this analysis,
while 32% continued to receive treatment.We also identified
differences in OS between TBP and non-TBP patients (24-
month OS rate, 59% and 25%, respectively). The safety pro-
file associatedwith TBPwas similar to that reported in a large
pooled analysis of data from 576 patients who received niv-
olumab monotherapy.15 Patients who continued nivolumab
therapywere less likely than non-TBP patients to require any
subsequent cancer therapy andweremore likely to have sur-
gery, which could suggest that nivolumab TBP resulted in tu-
mor shrinkage that allowed for surgical resection or that pro-
gression was isolated and not reflective of the total tumor
burden.
Atypical response patterns have been noted in patients
treated with nivolumab beyond RECIST-defined progression
in melanoma,7,16 non–small-cell lung cancer,17 and renal cell
carcinoma.18,19Theyhavealsobeenobservedwithuseofother
immunecheckpoint inhibitors,8,9,20,21 although it isworthnot-
ing that we found delayed response to be rare after 24 weeks
in patients treated beyond progression. Immune-related re-
sponse criteria (irRC) were proposed to enable more appro-
priate monitoring of response in patients receiving immuno-
therapy. These criteria base antitumor response on total
measurable tumor burden, so that the appearance of new le-
sions, for example, would not necessarily represent progres-
sive disease if accompanied by anoverall reduction in burden
of all measurable lesions. To date, trials of immune check-
point inhibitors havenot consistently reported response rates
Table 2. Treatment-Related Select Adverse Events (AEs)a,b
AE Type
No. (%)
Non-TBP (n = 221) TBP (n = 85)
Any Grade Grade 3-4 Any Grade Grade 3-4
All treatment-related select AEs 97 (44) 9 (4) 57 (67) 5 (6)
Skin 58 (26) 2 (1) 43 (51) 1 (1)
Pruritus 25 (11) 1 (<1) 23 (27) 0
Rash 23 (10) 0 23 (27) 0
Gastrointestinal 32 (14) 2 (1) 18 (21) 1 (1)
Diarrhea 31 (14) 2 (1) 18 (21) 1 (1)
Colitis 1 (<1) 0 1 (1) 0
Endocrine 18 (8) 1 (<1) 13 (15) 1 (1)
Hypothyroidism 13 (6) 0 7 (8) 0
Hyperthyroidism 5 (2) 1 (<1) 5 (6) 0
Hepatic 7 (3) 4 (2) 5 (6) 2 (2)
Alanine aminotransferase increased 3 (1) 2 (1) 1 (1) 0
Aspartate aminotransferase increased 2 (1) 1 (<1) 1 (1) 0
Pulmonary 3 (1) 0 2 (2) 0
Pneumonitis 2 (1) 0 1 (1) 0
Renal 4 (2) 0 0 0
Blood creatinine increased 2 (1) 0 0 0
Renal failure 2 (1) 0 0 0
Abbreviation: TBP, treatment beyond
progression.
a Most common select AEs (defined
as those with a potential
immunologic cause) in each organ
category are listed.
b These data were not adjusted for
differences in treatment exposure.
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based on the irRC, and rigorous comparison of clinical out-
comes using RECIST and irRC has not been made. Although
irRC are not likely to be widely used in clinical practice, they
have helped to raise awareness of atypical response patterns
with immune checkpoint inhibitors and that stopping treat-
ment at first signs of apparent tumor progression may be in-
appropriate in a patient who is otherwise tolerating treat-
ment well. For example, ipilimumab treatment may result in
delayed onset of effect, and some patients who initially re-
sponded or had stable disease with ipilimumab, but later ex-
perienced disease progression, achieved further disease con-
trol on ipilimumab retreatment.22
In our analysis, 24 patients had greater than 30% tumor
reduction in target lesion after progression when compared
with baseline, representing approximately 5% of all patients
allocated tonivolumabmonotherapy (N = 526),which is con-
sistent with known estimates of atypical immune-related
response patterns observed in other anti–PD-1 studies
(approximately 7%-9%).7-9 Two main hypotheses have been
proposed to account for the apparent disease progression
(“pseudoprogression”) that sometimesprecedes responses in
patients treatedwith immunecheckpoint inhibitors.5First, pa-
tientswith relativelyhigh immune suppressionwithin the tu-
mor microenvironment may have a comparatively slow anti-
tumor immune response that isultimately sufficient to reduce
tumor burden, allowing for continued tumor growth of target
lesions or the appearance of new lesions in the interim. Alter-
natively, treatmentmay induce a transient immune cell infil-
tration into the tumor, accompanied by edema, giving the ap-
pearance of increased tumor burden on imaging. This type of
inflammatory reaction has been confirmed by biopsy in pa-
tients treated with ipilimumab5,23,24 and in patients treated
with anti–PD-1 combination therapy.25 Because disease pro-
gression is definedbyRECIST as a 20%ormore increase in tu-
mor target lesion size or the appearance of new lesions, an in-
flammatory reactionwith immunecheckpoint therapymaybe
mistaken for disease progression, leading to treatment dis-
continuation before realization of treatment benefits.26
Tworetrospectiveanalysesof theefficacyandsafetyofniv-
olumab in patients with renal cell carcinoma treated beyond
progression18,19 suggested that continued nivolumab treat-
ment benefited a proportion of patients in terms of tumor re-
duction, as well as longermedian OS comparedwith patients
not treated beyond progression, with no new or unexpected
AEs observed.A third analysis of the samephase 3data by the
US Food and Drug Administration defined TBP differently,27
thus resulting in a lower number of patients with progressive
disease followed by a decrease of at least 30% in tumor after
continued treatmentwithnivolumab.Nevertheless, similar to
our findings, the investigators’decisionto treatwithnivolumab
beyond progression may have been based in part on patient
characteristics, such that patients with poor clinical charac-
teristics were unlikely to receive continued treatment. In our
analysis,patientswhohad, forexample,LDHlevelgreater than
ULN at progression, or an increase in target lesions and ap-
pearanceofnewlesionsatprogressiontogether,were less likely
than thosewithout these characteristics to be treated beyond
progression. Similarly, in the aforementioned renal cell carci-
noma analysis, patients with high incidence of new bone le-
sions and low quality of life scores were less likely than those
without these characteristics to be considered for continued
nivolumab treatment.18,19 Additional evaluationof factors in-
fluencing thedecision to continue treatment beyondprogres-
sion (eg, lack of other alternatives at the time of the decision)
may help investigators to identify appropriate candidates for
this approach.
Limitations
Although our analysis provides insights into the extended use
ofnivolumabbeyonddiseaseprogression, interpretationofthese
results is limited by several factors, including the use of retro-
spectivedata, therelativelysmallnumberofpatients treatedbe-
yonddiseaseprogression,andselectionofpatients forextended
treatment by investigators basedon factors that havenot been
systematically explored. In the absence of randomized data, it
is unclear that these patients would not have survived as long
withoutbeingexposed to furthernivolumabtreatment.Future
studiesshouldexamineoutcomesamongpatientstreatedbeyond
diseaseprogressioninlarge,prospectivecohortsthatarerandom-
izedonprogression to further treatmentor toobservationonly.
Randomizedtrialswouldalsoallowforbetterassessmentof the
safetyofcontinuedtreatmentcomparedwithalternativecareon
progression.AlthoughnoneworunexpectedAEswereobserved
in patients treated beyond progression in our analysis, contin-
ued treatmentmay be associatedwith risks, as observed in re-
nal cell carcinoma.27
Conclusions
In summary, our analysis shows that patients treated beyond
their first disease progression can experience a tumor re-
sponsewithcontinuednivolumabtreatment,withasafetypro-
file consistent with that observed in patients who did not re-
ceive further treatment. Although patients selected for
continued treatmentwere typically healthier than thosewho
were not selected, it is possible that patients with less favor-
ableclinical characteristicswouldhavealsobenefited fromfur-
ther nivolumab therapy after progression. The results of this
analysis suggest thatcontinuedtreatmentwithnivolumabmay
beanoptiontoachieve furtherapparentclinicalbenefit insome
patients with advanced melanoma.
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